Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus (DM), affecting approximately 50% of diabetic patients. It causes nerve damage, leading to pain, numbness, and sensory loss, significantly impacting patients' quality of life. With the increasing prevalence of diabetes, the demand for advanced diabetic peripheral neuropathy therapeutics is rising. The pipeline for DPN drugs is expanding, focusing on alternative therapies that provide effective pain relief and nerve protection. Growing research initiatives and technological advancements are expected to drive market growth in the coming years, offering promising diabetic peripheral neuropathy drug candidates and improved treatment options.
Major companies involved in the diabetic peripheral neuropathy pipeline analysis market include Eli Lilly and Company, Eurofarma Laboratorios S.A., and others.
Leading drugs currently in the pipeline include N0750, LY3556050, YJ001, and others.
The growth of the diabetic peripheral neuropathy drug pipeline is driven by the rising prevalence of diabetes, increased demand for effective pain management, and advancements in novel therapies focusing on nerve protection and regeneration.
The Diabetic Peripheral Neuropathy Pipeline Insight Report by Expert Market Research gives comprehensive insights into diabetic peripheral neuropathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic peripheral neuropathy. The diabetic peripheral neuropathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The diabetic peripheral neuropathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with diabetic peripheral neuropathy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to diabetic peripheral neuropathy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Diabetic peripheral neuropathy is a common complication of diabetes caused by prolonged high blood sugar levels, damaging peripheral nerves. It typically affects the feet and legs, leading to numbness, tingling, pain, or weakness. Poor blood circulation and metabolic factors also contribute to nerve damage, increasing the risk of infections, ulcers, and mobility issues in severe cases.
Diabetic peripheral neuropathy treatments focus on managing symptoms and slowing progression. Blood sugar control is crucial to prevent further nerve damage. Medications like antidepressants, anticonvulsants, and pain relievers provide symptom relief. Lifestyle changes, including regular exercise and a balanced diet, are recommended. In advanced cases, physical therapy and specialized foot care help maintain function and prevent complications. Lyrica (pregabalin), Cymbalta (duloxetine), Nucynta (tapentadol), and Qutenza (capsaicin) are currently approved by the Food and Drug Administration for treating pain associated with diabetic peripheral neuropathy.
Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus (DM), affecting approximately 50% of diabetic patients, depending on disease duration and glucose control. In 2021, 38.4 million people in the United States (11.6% of the population) had diabetes. The United Kingdom reported 4.3 million cases. India had over 74 million diabetics in 2021, projected to exceed 124 million by 2045.
This section of the report covers the analysis of diabetic peripheral neuropathy drug candidates based on several segmentations, including:
By Phase
The pipeline report covers 50+ drug analyses based on phase:
By Drug Class
The diabetic peripheral neuropathy pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases.
According to EMR analysis, phase II with 57.89%, covers a major share of the total diabetic peripheral neuropathy clinical trials. Phase III holds 18.42%, indicating advancement toward regulatory approval. Phase I and phase IV contribute around 10.53%, reflecting a balanced focus on early-stage safety and post-marketing studies. Early phase I represents 2.63%. This robust pipeline can positively accelerate innovation and market growth in diabetic peripheral neuropathy treatment.
The drug molecule categories covered under the diabetic peripheral neuropathy pipeline analysis include small molecules, gene therapies, monoclonal antibodies, peptides, and recombinant fusion proteins. The diabetic peripheral neuropathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diabetic peripheral neuropathy. Sodium channel inhibitors are emerging as a novel drug class for diabetic peripheral neuropathy (DPN). For example, Suzetrigine (VX-548), an oral selective NaV1.8 pain signal inhibitor, is advancing in the pipeline. The compound also holds a breakthrough therapy designation from the United States Food and Drug Administration.
The EMR report for the diabetic peripheral neuropathy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed diabetic peripheral neuropathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in diabetic peripheral neuropathy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for diabetic peripheral neuropathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of diabetic peripheral neuropathy drug candidates.
N0750 is an investigational drug candidate developed by Eurofarma Laboratórios S.A. It is currently undergoing a Phase III clinical trial to evaluate its efficacy and safety in treating painful diabetic peripheral neuropathy (PDPN). This study aims to determine whether N0750 is superior to monotherapies like Cymbalta® (duloxetine) and Lyrica® (pregabalin) in reducing pain intensity over 12 weeks. The trial is expected to enroll 666 patients and conclude by March 2028.
LY3556050, developed by Eli Lilly and Company, is currently being evaluated in a Phase 2 clinical trial for diabetic peripheral neuropathic pain (DPNP). This study aims to assess the safety and efficacy of LY3556050 compared to a placebo over approximately 24 weeks. LY3556050 likely targets specific pain pathways, potentially reducing pain signals and improving patient outcomes. The study completion is estimated by July 2025, with 410 participants enrolled. LY3556050 is a selective SSTR4 agonist that targets peripheral nociceptive pathways, aiming to reduce chronic diabetic peripheral neuropathic pain through oral administration.
YJ001 for Spray Use is a topical drug sponsored by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. This Phase I, randomized, double-blind, placebo-controlled study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of YJ001 in patients with diabetic peripheral neuropathic pain (DPNP). The drug is administered as multiple sprays on both feet to determine the optimal therapeutic dose for effective pain relief. YJ001 is a topical spray that helps in reducing diabetic neuropathic pain by delivering localized relief while minimizing systemic exposure and side effects.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Diabetic Peripheral Neuropathy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for diabetic peripheral neuropathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into diabetic peripheral neuropathy collaborations, regulatory environments, and potential growth opportunities.
Global Diabetic Neuropathy Market Report and Forecast
Global Diabetic Neuropathy Treatment Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share